The US drugmaker Impax Laboratories is acquiring two generic medicines from the Dublin-based pharmaceutical group Actavis, as part of the latter’s requirements to divest four of its medicines in order…
Impax boosts portfolio with Actavis buys
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at firstname.lastname@example.org and we will call you to discuss.
Already a subscriber? Login here